Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Recently Published: Reports on Policy Options for Formulary Development in Middle-income Countries and A Case Study from Mexico
4 January 2017
OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to…
Age and Utilities: Issues for HTA
1 April 2017
Several studies have found differences in health state values by age. We investigate whether and how age affects respondents’ Time Trade-Off (TTO) and Visual Analogue Scale…
How can HTA meet the needs of health system and government decision makers?
4 January 2017
The 2015 meeting of the HTAi Asia Policy Forum meeting was held in Singapore, 29th -30th October 2015. The topic of the meeting was: How can…
Transferability of HTA
4 January 2017
The second HTAi Asia Policy Forum meeting (2014) was held in Manilla, 10th -11th June 2014. The topic of the meeting was: Transferability of HTA. This…
HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
4 January 2017
The HTAi Asia Policy Forum meeting 2013 was held in Seoul, 13th -14th June 2013. This was the first of several annual meetings of the HTAi…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and…
Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets
1 March 2017
Three EQ-5D value sets (the EQ-5D-3L, crosswalk and EQ-5D-5L) are now available for cost utility analysis in the UK and/or England. The value sets’ characteristics differ,…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The…
Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
20 December 2016
This paper uses MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and then uses these preferences to…